8. Biochemical profile: Acute care, hepatic and mineral panel as described in Sections 2.2 and 2.4. 9. Evaluate CEA, CA19-9, CA125 and CA15-3 at baseline and follow elevated values thereafter (for participants enrolled on the phase I portion of the protocol). 10. In HIV positive participants. 11. Every 8 weeks for participants. 12. Imaging will be performed every 8 weeks. In the event of a PR or CR tumor imaging assessments may be performed every 3 months (+/- 2 weeks) at the discretion of the investigator. Tumor assessment should be continued beyond end of treatment in participants who have not experienced PD until they experience PD in order to assess PFS. MRI (with gadolinium) will be used when CT scan is not an option to follow the disease. Bone scans and other imaging assessments may also be performed as clinically indicated. 41 Abbreviated Title: Combo Immunotx in HPV OPSCC Version Date: 04.25.2023 13. In participants with known CNS disease as described in Section 2.1.2.3; MRIs may be performed as clinically indicated in this population.